Vonoprazan (Voquezna) for Nonerosive GERD
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1713c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Sulfonamides, Proton Pump Inhibitors, Pyrroles.
Abstract (Originalsprache)
The potassium-competitive acid blocker vonoprazan (Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) in adults.1 Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Vonoprazan (Voquezna) for Nonerosive GERD. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1713c
Vancouver
Vonoprazan (Voquezna) for Nonerosive GERD. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1713c
BibTeX
@article{euvimed2024,
title = {Vonoprazan (Voquezna) for Nonerosive GERD},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1713c}
}
EUVIMED